Firebrick Pharma Limited Announces That Its Planned Clinical Trial of Nasodine Nasal Spray (Povidone-Iodine 0.5%) in Covid-19 Patients in South Africa, Had Received Approval to Proceed from the South African Health Products Regulatory Authority

Firebrick Pharma Limited announced that its planned clinical trial of Nasodine Nasal Spray (povidone-iodine 0.5%) in COVID-19 patients in South Africa, had received approval to proceed from the South African Health Products Regulatory Authority (SAHPRA). The trial is titled: "Reduction of nasal shedding of SARS-CoV-2 in COVID-19 positive patients by the use of Nasodine® (povidone-iodine 0.5%) Nasal Spray." It is intended to demonstrate that frequent, repeated application of Nasodine Nasal Spray ("Nasodine") in COVID-19 subjects who are RAT-positive, leads to reduction or elimination of nasal shedding of the Sars-CoV-2 virus. The SAHPRA approval specifically allows Firebrick Pharma to import Nasodine into South Africa for the trial and to administer the product to patients during the trial, according to the trial protocol submitted to SAHPRA.

As noted in the Company's prospectus (section 2.4.4(b)), prior to commencing the trial the Company will also need approval from the local clinical Ethics Committee, which has been applied for but has yet to be received.